ALLSCHWIL/BASEL, SWITZERLAND - 04 May 2011 - At today's Annual General Meeting of Actelion Ltd (SIX: ATLN), held in Basel Switzerland, shareholders voted on a number of resolutions put forward by the Company's Board.
The meeting was attended by 339 shareholders, representing 56'756'369 shares or 43.31% of the total outstanding shares.
On behalf of the Board and all employees of Actelion, the Chairman of the Board, Jean-Pierre Garnier, thanked the departing Board member and long-serving Chairman of Actelion, Robert C. Cawthorn for his services.
Jean-Pierre Garnier, Chairman of the Board of Directors at Actelion, commented: "When Robert Cawthorn was elected as Chairman of Actelion, he brought with him an incredible amount of experience in life science."
Jean-Pierre Garnier concluded: "Two distinguishing features have characterized Rob's leadership as Chairman: First, and foremost, his strategic vision on how to transform innovation into a successful global business opportunity. Secondly, he made himself available to management to share his experience, not only as Chairman but also as coach and mentor. Rob's unwavering commitment to the company and shareholders earned the respect of all of us."
The shareholders approved the Business Report consisting of the Annual Report, the Annual Statutory Accounts and the Consolidated Accounts for the year 2011.
A proposal by the Board to distribute as a dividend, out of legal reserve originating from capital contribution, in the amount of CHF 0.80 per registered share was passed by the shareholders.
Actelion's shareholders endorsed the Compensation Report through a non-binding consultative vote.
The shareholders granted discharge to all members of the Board of Directors and of Senior Management.
A proposal by the Board to approve the reduction of the share capital by means of cancellation of the corresponding number of repurchased shares, as well as the amendment of the respective provision in the Company's Articles of Association, was passed by the shareholders.
Actelion's shareholders voted to re-elect Mr. Michael Jacobi to the Board for a term of three years.
The shareholders also voted to elect a new Director, Prof. Dr. Peter Gruss, to the Board for a term of three years.
Following the AGM, Actelion's Board comprises a total of ten members: Jean-Pierre Garnier (Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul Clozel, Carl Feldbaum, Peter Gruss, Werner Henrich, Michael Jacobi, Armin Kessler, and Jean Malo.
Finally, the shareholders confirmed Ernst & Young as the Company's statutory auditors for the year 2012.
Notes to the Editor
About Professor Gruss
Peter Gruss has been President of the Max Planck Society since 2002. He became a Scientific Member of the Max Planck Society in 1986, when he was appointed as Director at the Max Planck Institute for Biophysical Chemistry in Göttingen. He earned his PhD in biology at the University of Heidelberg and is honorary professor at the University of Göttingen.
Peter Gruss began his scientific career as a research assistant at the Institute for Virus Research in Heidelberg in 1977. From there, he moved on to the National Institutes of Health in Bethesda, Maryland, initially as a post-doc associate, and later as an expert consultant. In 1982, he was appointed as Professor at the Institute for Microbiology at the University of Heidelberg.
Over the years, he has received several honors, including the Leibniz Prize, the Louis-Jeantet Prize for Medicine, the German Prize for Technology and Innovation by the President of the Federal Republic of Germany, the Lower Saxony State Prize, as well as the German Federal Cross of Merit.
As President of the Max Planck Society, Peter Gruss holds numerous offices and functions. Among others, he is a member of the Senates of the Alliance of Scientific Organizations in Germany, the German Research Foundation (DFG), the German National Academy of Sciences Leopoldina, as well as of acatech, the German Academy of Science and Engineering. In addition, he is member of the Supervisory Boards of Siemens AG and Munich RE, as well as of the Advisory Board of Deloitte. He was appointed as a member of the "Innovation Dialogue" of the Federal Chancellery by Angela Merkel.
About the Max Planck Society
The Max Planck Society is Germany's most successful research organization. Since its establishment in 1948, no fewer than 17 Nobel laureates have emerged from the ranks of its scientists, putting it on a par with the best and most prestigious research institutions worldwide. The more than 13,000 publications each year in internationally renowned scientific journals are proof of the outstanding research work conducted at Max Planck Institutes -many of those articles are among the most-cited publications in their relevant fields.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,500 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).
For further information please contact:
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
Press Release PDF